Chemotherapy Schedules in Small Cell Lung Cancer
Author Information
Author(s): Burgers J A, Arance A, Ashcroft L, Hodgetts J, Lomax L, Thatcher N
Primary Institution: University Hospital Rotterdam, Department of Pulmonary Diseases
Hypothesis
Do patients treated within a trial protocol have better survival than those treated off study?
Conclusion
The study found no significant difference in survival between patients treated on trial and those treated off trial with the same chemotherapy regimen.
Supporting Evidence
- The median survival for all patients was 345 days.
- Patients treated on trial had a median survival of 346 days, while those off trial had 330 days.
- The study included 106 patients treated with the same chemotherapy regimen.
Takeaway
This study looked at patients with lung cancer and found that being in a clinical trial didn't help them live longer compared to those who weren't in the trial but got the same treatment.
Methodology
The study reviewed the records of patients treated with CDE chemotherapy at Christie Hospital and compared survival data of those treated on and off trial.
Potential Biases
Potential selection bias due to reasons for not entering the trial.
Limitations
The study was retrospective and had a limited number of patients.
Participant Demographics
Patients treated on and off trial did not differ significantly in demographic and prognostic factors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website